Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study

BACKGROUND: In patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC), growing evidence supports anti-epidermal growth factor receptor (EGFR) retreatment, whereas little is known on the outcomes of anti-EGFR-based reinduction therapy during the upfront strategy. METHODS: We included pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fucà, Giovanni, Raimondi, Alessandra, Prisciandaro, Michele, Lonardi, Sara, Cremolini, Chiara, Ratti, Margherita, Clavarezza, Matteo, Murialdo, Roberto, Sartore-Bianchi, Andrea, Smiroldo, Valeria, Berenato, Rosa, Racca, Patrizia, Bergamo, Francesca, Corallo, Salvatore, Di Bartolomeo, Maria, de Braud, Filippo, Morano, Federica, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842305/
https://www.ncbi.nlm.nih.gov/pubmed/35305093
http://dx.doi.org/10.1093/oncolo/oyab012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842305/
https://www.ncbi.nlm.nih.gov/pubmed/35305093
http://dx.doi.org/10.1093/oncolo/oyab012

Ejemplares similares